Keppra 250mg GSK tablets treat local seizures (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Levetiracetam

Ingredient

Composition information	Content
Levetiracetam	250mg

Uses

indications

Keppra 250 mg drug is indicated in the following cases:

Single therapeutic treatment: The local seizures have or without mucous chemicals in the people and teenagers aged 16 and older to be diagnosed with epilepsy.

Coordination treatment in the following cases:

Local sperm episodes with or without menside secondary to adults, minority and children aged 4 and older with epilepsy.

Muscle seizures in adults and teenagers aged 12 and older suffer from teenage muscle epilepsy (Juvenile Myoclonic Epileepsy).

Summoning elevation of all adults and teenagers aged 12 and older are involved in the whole steadily epilepsy.

Pharmacy

The mechanism of action of levetiracetam has not been fully explained.

Levetiracetam enhances protection against seizures in many models of local seizures and the entire elementary aroma on animals without seizures. Main metabolites are not active.

In humans, the drug works in both local and whole epilepsy (epilepsy discharge/ response to light stimulation) that confirms the widespread pharmacological characteristics of levetiracetam.

pharmacokinetics

absorption:

levetiracetam is quickly absorbed after drinking. Bioions reach nearly 100%. The level of absorption does not depend on the dose and is not affected by food.

Distribution:

both levetiracetam and its main metabolites are not significantly connected to plasma proteins (

Metabolism:

In humans, levetiracetam is not widely metabolized. The main metabolic path (24% of the dose) is to hydrolyze acetamide with yeast.

Era:

Semi -cancellation time in adults is 7 ± 1 hour. The main elimination road is through the urinary road, accounting for an average of 95% of the dose, only 0.3% of the dosage dosage through feces.

Before taking Keppra 250mg GSK tablets treat local seizures (3 blisters x 10 tablets)

How to use

use orally, swallow with enough water and can be taken during or outside meals. The daily dose is divided equally for 2 drinks.

Dosage

adults:

Single therapy:

Adults and teenagers aged 16 and over:

The starting dose is recommended as 250 mg twice daily and increases to the treatment dose from the head 500 mg twice a day after 2 weeks.

This dose may increase by 250 mg twice daily for every 2 weeks depending on the clinical response.

The maximum dose is 1500 mg twice daily.

combined treatment:

Adults (18 years old) and teenagers (12 to 17 years old) weighing 50 kg or more:

The initial treatment dose is 500 mg twice daily.

This dose may start from the first day of treatment. Depending on the clinical response and ability to tolerate drugs, daily dose can be increased to 1500 mg twice daily.

Can adjust the dose increases or decreases to 500 mg twice daily for every 2 to 4 weeks.

Children:

Doctors should prescribe prescription, presentation and the most appropriate drug content based on age, weight and dose.

The type of tablet is not suitable for children under 6 years old and is not suitable for initial treatment in children weighing less than 25 kg, patients cannot swallow tablets or dose less than 250 mg.

Children and children under 4 years old:

There is no enough data to recommend using levetiracetam for children under 4 years old.

Single therapy:

has not established the safety and effectiveness of levetiracetam in monomers in children and teenagers under 16 years old.

combined treatment for children from 4 to 11 years old and teenagers (12 to 17 years old) weighing less than 50 kg:

The initial treatment dose is 10 mg/kg twice daily.

Depending on clinical response and tolerance ability, the dose can be increased to 30 mg/kg twice daily. The level of adjustment of the dose increases or decreases should not exceed 10 mg/kg twice daily for every 2 weeks. Should use the lowest dose effectively.

Dosage in children from 50 kg or more is similar to adult dose.

recommendations on dosage for children and teenagers

Weight Starting dose: 10 mg/kg Two daily Maximum dose: 30 mg/kg twice daily 500 mg twice daily 1500 mg twice daily

Recommendations to adjust the dose in elderly patients with impaired renal function.

kidney failure:

Daily dose must be adjusted for each patient based on kidney function:

Dosage adjustment for adults and adolescents over 50 kg or more is impaired kidney function:

Creatinine clearance (ml/min/1.73m2) Dosage and number of times used Light 50 - 79 500 to 1000 to 1000 mg twice daily Date

Patients with end -stage renal disease - must be feces (1)

500 to 1000 mg once a day

Creatinine clearance (ml/min/1.73m2)

Dosage and number of times used Lightweight 50-79 10 to 20 mg/kg twice daily Date
Patients with end-stage renal disease-must be sub-sanctions - 10 to 20 mg/kg once a day
No dose adjustment for patients with mild to moderate liver failure. For patients with severe hepatic failure, it is recommended to reduce the daily daily maintenance of creatinine under 60 ml/min/1.73m2.
Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What do
do when using an overdose? There is no specific antidote for levetiracetam.
Overdose is mainly symptomatic treatment and may include hemorrhage. Separation machine efficiency is 60% for levetiracetam and 74% for main metabolites.
Continuing management should be indicated based on clinical or recommended by the National Poison Control Center, when needed.
What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Keppra 250 mg, you may experience unwanted effects (ADR).

Common, ADR> 1/100

Infections and parasites: Nasomitis.

Blood disorders and lymphatic systems: thrombocytopenia, leukopenia.

Metabolic disorders and nutrition: Anorexia, weight loss, weight gain.

Mental disorders: depression, anti -rule, anxiety, insomnia, restless/stimulating, suicide efforts, suicide intentions, mental disorders, abnormal behaviors, hallucinations, anger, confusion state, panic, emotional instability/mood change, anxiety.

Eyes: Song Thi, blurred vision.

Respiratory: cough.

Digestive: abdominal pain, diarrhea, indigestion, vomiting, nausea.

Liver, bile: Examination of abnormal liver function.

Skin and subcutaneous tissue: rash, hair loss, eczema, itching.

bones and connective tissue: muscle weakness, muscle pain.

Body and on -site: weakness, fatigue.

Uncommon, 1/1000

No information.

Instructions on how to handle ADR

Notify the doctor with unwanted effects when using the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Keppra drug 250 mg is contraindicated in the following cases: Hypersensitivity to active ingredients or other derivatives of pyrroolidone or any excipients of the drug.

Be cautious when using

Stop drug stop: If you have to stop treating with levetiracetam, it is recommended to gradually reduce the dose.

Renal failure or liver failure: The dose should be adjusted when using levetiracetam for patients with renal impairment. For patients with severe liver failure, recommendation of kidney function before choosing the dose.

Depression and/or suicide intentions: Should monitor depression signs and/or intentions and suicidal behavior of the patient and consider appropriate treatment.

Children: The type of tablet is not suitable for use in children under 6 years old. It is unclear long -term impact on the ability to study, intelligence, development, endocrine function, puberty and fertility in children.

The ability to drive and operate machinery

levetiracetam has little impact or impact on the ability to drive and operate machinery, so be cautious. Advise patients to drive or operate machinery until confirming that the ability to perform these activities is not affected.

pregnancy

do not recommend levetiracetam during pregnancy and in women who are likely to get pregnant without using contraception, unless necessary.

Lactating period

levetiracetam is excreted through breast milk. Therefore, it is not recommended for breastfeeding while taking the drug. However, if you need treatment with levetiracetam during breastfeeding, you should consider the benefits/ risks of treatment compared to the importance of breastfeeding.

Drug interaction

anti -epileptic drugs:

levetiracetam does not affect the serum concentration of anti -epileptic drugs (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and these anti -epileptic drugs do not affect the pharmacokinetics of levetiracetam.

Probenecid:

Probenecid (dose of 500 mg 4 times daily) inhibits the kidney removal mode of the original metabolic substance but does not inhibit the renal clearance of levetiracetam.

methotrexate:

Concomitance of Levetiracetam and Methotrexate has been reported to reduce the clearance of the clearance of methotrexate. The risk of toxicity.

Oral contraceptives, digoxin and warfarin:

Concentrated with digoxin, oral contraceptives and warfarin does not affect the pharmacokinetics of levetiracetam.

Food:

Levetiracetam's absorption level is not affected by food but the absorption speed is slightly reduced.

Storage

Storage below 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.